112TH CONGRESS 

1ST SESSION H. R. 1254 

AN ACT 

To amend the Controlled Substances Act to place synthetic 

drugs in Schedule I. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 
2 

•HR 1254 EH

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Synthetic Drug Con3 trol Act of 2011’’. 

4 SEC. 2. ADDITION OF SYNTHETIC DRUGS TO SCHEDULE I 

5 OF THE CONTROLLED SUBSTANCES ACT. 

6 (a) CANNABIMIMETIC AGENTS.—Schedule I, as set 

7 forth in section 202(c) of the Controlled Substances Act 

8 (21 U.S.C. 812(c)) is amended by adding at the end the 

9 following: 

10 ‘‘(d)(1) Unless specifically exempted or unless listed 

11 in another schedule, any material, compound, mixture, or 

12 preparation which contains any quantity of 

13 cannabimimetic agents, or which contains their salts, iso14 mers, and salts of isomers whenever the existence of such 

15 salts, isomers, and salts of isomers is possible within the 

16 specific chemical designation. 

17 ‘‘(2) In paragraph (1): 

18 ‘‘(A) The term ‘cannabimimetic agents’ means 

19 any substance that is a cannabinoid receptor type 1 

20 (CB1 receptor) agonist as demonstrated by binding 

21 studies and functional assays within any of the fol22 lowing structural classes: 

23 ‘‘(i) 2-(3-hydroxycyclohexyl)phenol with 

24 substitution at the 5-position of the phenolic 

25 ring by alkyl or alkenyl, whether or not sub26 stituted on the cyclohexyl ring to any extent. 
3 

•HR 1254 EH

1 ‘‘(ii) 3-(1-naphthoyl)indole or 3-(1- 

2 naphthylmethane)indole by substitution at the 

3 nitrogen atom of the indole ring, whether or not 

4 further substituted on the indole ring to any ex5 tent, whether or not substituted on the naph6 thoyl or naphthyl ring to any extent. 

7 ‘‘(iii) 3-(1-naphthoyl)pyrrole by substi8 tution at the nitrogen atom of the pyrrole ring, 

9 whether or not further substituted in the 

10 pyrrole ring to any extent, whether or not sub11 stituted on the naphthoyl ring to any extent. 

12 ‘‘(iv) 1-(1-naphthylmethylene)indene by 

13 substitution of the 3-position of the indene ring, 

14 whether or not further substituted in the indene 

15 ring to any extent, whether or not substituted 

16 on the naphthyl ring to any extent. 

17 ‘‘(v) 3-phenylacetylindole or 3- 

18 benzoylindole by substitution at the nitrogen 

19 atom of the indole ring, whether or not further 

20 substituted in the indole ring to any extent, 

21 whether or not substituted on the phenyl ring 

22 to any extent. 

23 ‘‘(B) Such term includes— 

24 ‘‘(i) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3- 

25 hydroxycyclohexyl]-phenol (CP–47,497); 
4 

•HR 1254 EH

1 ‘‘(ii) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3- 

2 hydroxycyclohexyl]-phenol (cannabicyclohexanol 

3 or CP–47,497 C8-homolog); 

4 ‘‘(iii) 1-pentyl-3-(1-naphthoyl)indole 

5 (JWH–018 and AM678); 

6 ‘‘(iv) 1-butyl-3-(1-naphthoyl)indole (JWH– 

7 073); 

8 ‘‘(v) 1-hexyl-3-(1-naphthoyl)indole (JWH– 

9 019); 

10 ‘‘(vi) 1-[2-(4-morpholinyl)ethyl]-3-(1-naph11 thoyl)indole (JWH–200); 

12 ‘‘(vii) 1-pentyl-3-(2- 

13 methoxyphenylacetyl)indole (JWH–250); 

14 ‘‘(viii) 1-pentyl-3-[1-(4- 

15 methoxynaphthoyl)]indole (JWH–081); 

16 ‘‘(ix) 1-pentyl-3-(4-methyl-1-naph17 thoyl)indole (JWH–122); 

18 ‘‘(x) 1-pentyl-3-(4-chloro-1-naph19 thoyl)indole (JWH–398); 

20 ‘‘(xi) 1-(5-fluoropentyl)-3-(1-naph21 thoyl)indole (AM2201); 

22 ‘‘(xii) 1-(5-fluoropentyl)-3-(2- 

23 iodobenzoyl)indole (AM694); 

24 ‘‘(xiii) 1-pentyl-3-[(4-methoxy)-ben25 zoyl]indole (SR–19 and RCS–4); 
5 

•HR 1254 EH

1 ‘‘(xiv) 1-cyclohexylethyl-3-(2- 

2 methoxyphenylacetyl)indole (SR–18 and RCS– 

3 8); and 

4 ‘‘(xv) 1-pentyl-3-(2- 

5 chlorophenylacetyl)indole (JWH–203).’’. 

6 (b) OTHER DRUGS.—Schedule I of section 202(c) of 

7 the Controlled Substances Act (21 U.S.C. 812(c)) is 

8 amended in subsection (c) by adding at the end the fol9 lowing: 

10 ‘‘(18) 4-methylmethcathinone (Mephedrone). 

11 ‘‘(19) 3,4-methylenedioxypyrovalerone (MDPV). 

12 ‘‘(20) 3,4-methylenedioxymethcathinone 

13 (methylone). 

14 ‘‘(21) Naphthylpyrovalerone (naphyrone). 

15 ‘‘(22) 4-fluoromethcathinone (flephedrone). 

16 ‘‘(23) 4-methoxymethcathinone (methedrone; 

17 Bk–PMMA). 

18 ‘‘(24) Ethcathinone (N-Ethylcathinone). 

19 ‘‘(25) 3,4-methylenedioxyethcathinone 

20 (ethylone). 

21 ‘‘(26) Beta-keto-N-methyl-3,4- 

22 benzodioxyolybutanamine (butylone). 

23 ‘‘(27) N,N-dimethylcathinone 

24 (metamfepramone). 
6 

•HR 1254 EH

1 ‘‘(28) Alpha-pyrrolidinopropiophenone (alpha2 PPP). 

3 ‘‘(29) 4-methoxy-alpha4 pyrrolidinopropiophenone (MOPPP). 

5 ‘‘(30) 3,4-methylenedioxy6 alphapyrrolidinopropiophenone (MDPPP). 

7 ‘‘(31) Alpha-pyrrolidinovalerophenone (alpha8 PVP). 

9 ‘‘(32) 6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol10 6-amine) (MDAI). 

11 ‘‘(33) 3-fluoromethcathinone. 

12 ‘‘(34) 4’-Methyl-α-pyrrolidinobutiophenone 

13 (MPBP). 

14 ‘‘(35) 2-(2,5-Dimethoxy-4- 

15 ethylphenyl)ethanamine (2C–E). 

16 ‘‘(36) 2-(2,5-Dimethoxy-4- 

17 methylphenyl)ethanamine (2C–D). 

18 ‘‘(37) 2-(4-Chloro-2,5- 

19 dimethoxyphenyl)ethanamine (2C–C). 

20 ‘‘(38) 2-(4-Iodo-2,5- 

21 dimethoxyphenyl)ethanamine (2C–I). 

22 ‘‘(39) 2-[4-(Ethylthio)-2,5- 

23 dimethoxyphenyl]ethanamine (2C–T–2). 

24 ‘‘(40) 2-[4-(Isopropylthio)-2,5- 

25 dimethoxyphenyl]ethanamine (2C–T–4). 
7 

•HR 1254 EH

1 ‘‘(41) 2-(2,5-Dimethoxyphenyl)ethanamine (2C– 

2 H). 

3 ‘‘(42) 2-(2,5-Dimethoxy-4-nitro4 phenyl)ethanamine (2C–N). 

5 ‘‘(43) 2-(2,5-Dimethoxy-4-(n)- 

6 propylphenyl)ethanamine (2C–P).’’. 

7 SEC. 3. TEMPORARY SCHEDULING TO AVOID IMMINENT 

8 HAZARDS TO PUBLIC SAFETY EXPANSION. 

9 Section 201(h)(2) of the Controlled Substances Act 

10 (21 U.S.C. 811(h)(2)) is amended— 

11 (1) by striking ‘‘one year’’ and inserting ‘‘2 

12 years’’; and 

13 (2) by striking ‘‘six months’’ and inserting ‘‘1 

14 year’’. 

Passed the House of Representatives December 8, 

2011. 

Attest: 

Clerk. 
112TH CONGRESS 

1ST SESSION H. R. 1254 

AN ACT 

To amend the Controlled Substances Act to place 

synthetic drugs in Schedule I.